Atossa Therapeutics completed enrollment of phase 1 clinical study of AT-301 Coronavirus nasal spray
On Oct. 19, 2020, Atossa Therapeutics announced it had completed enrollment in its Phase 1 clinical study using…
On Oct. 19, 2020, Atossa Therapeutics announced it had completed enrollment in its Phase 1 clinical study using…
On Oct. 16, 2020, the NIH launched an adaptive Phase 3 clinical trial to evaluate the safety and…
On Oct. 16, 2020, BD (Becton, Dickinson) announced the CE mark and European availability of a product for…
On Oct. 16, 2020, the U.S. Department of Defense in coordination with the Department of Health and Human…
On Oct. 15, 2020, Entos Pharmaceuticals announces that its San Diego-based spinout company Aegis Life, will pursuing U.S….
On Oct. 15, 2020, the World Health Organization (WHO) announced Interim that results from the Solidarity Therapeutics Trial,…
On Oct. 15, 2020, scientists from the University of Oxford’s Department of Physics announced they had developed an…
On Oct. 15, 2020, Eiger BioPharmaceuticals announced results of the ILIAD Study (Interferon Lambda for Immediate Antiviral Therapy…
On Oct. 15, 2020, ImmunityBio announced it had received authorization from the FDA to begin a Phase I…
On Oct. 15, 2020, Ionis Pharmaceuticals announced that IONIS-PKK-LRx was being evaluated in an investigator-initiated Phase 2 clinical…
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
On Nov. 9, 2020, after more than two years of reconstruction efforts, scientists from the Fred Hutchinson Cancer…
On Oct. 15, 2020 teams from two divisions of the Allen Institute, the Allen Institute for Cell Science…
On Oct. 14, 2020, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
On Oct. 14, 2020, the World Health Organization (WHO) announced that prior to the COVID-19 pandemic, many countries…
On Oct. 14, 2020, recognizing the urgent need for new tools to combat vector-borne diseases (VBDs), and in…
On Oct. 14, 2020, the FDA approved Regeneron Pharmaceutical’s Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three…
On Oct. 14, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD)…
On Oct. 14, 2020, Vaxart announced that the FDA had completed its review of the Companyメs Investigational New…
On Oct. 14, 2020, Thermo Fisher Scientific announced plans to develop two new sterile filling lines in Singapore…
On Oct. 14, 2020, Moderna announced that it had received written confirmation from the European Medicines Agency (EMA)…
On Oct. 14, 2020, 3M and Discovery Education announced they had named 14-year-old Anika Chebrolu from Frisco, Texas,…
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
On Oct. 14, 2020, Regeneron announced that the FDA had approved Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) for the…
On Oct. 14, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from the Phase 1 portion of…
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…